Hernandez, Israel <br/><br/>
A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy.  [electronic resource] 

 -  Science translational medicine  03 2019 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1946-6242 
<br/><br/><label>Standard No.: </label>10.1126/scitranslmed.aat3005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Brain--drug effects<br/>Disease Models, Animal<br/>Enzyme Inhibitors--pharmacology<br/>Farnesyltranstransferase--antagonists & inhibitors<br/>Female<br/>GTP-Binding Proteins--antagonists & inhibitors<br/>Humans<br/>Induced Pluripotent Stem Cells--drug effects<br/>Lysosomes--drug effects<br/>Male<br/>Mice<br/>Mice, Transgenic<br/>Mutation<br/>Neurons--drug effects<br/>Piperidines--pharmacology<br/>Proteolysis--drug effects<br/>Pyridines--pharmacology<br/>RNA, Small Interfering--genetics<br/>Tauopathies--drug therapy<br/>Translational Research, Biomedical<br/>tau Proteins--genetics